Clinical trials: Dementia, Senile
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Mental Health Issue
Delivery Format of Cognitive Behavioral Therapy Materials on Engagement and Outcomes: AI-Enabled App vs PDF Workbook
The goal of this clinical trial is to compare two different ways of delivering cognitive behavioral therapy (CBT) materials to people with symptoms of anxiety and depression. The main questions it aims to answer are: 1.
- Trial name
- NCT06459128
- Testing
- Limbic Care, Digital Workbook
- Where
- United Kingdom
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Limbic Limited
Alzheimer Disease
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks.
- Trial name
- REFOCUS-ALZ (NCT05026177)
- Testing
- Simufilam
- Where
- 89 sites in United States, Canada and 2 more
- Volunteers
- 1,125 people
- Sponsor
- Cassava Sciences, Inc.
Chronic Insomnia
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
- Trial name
- NCT00325728
- Testing
- Ramelteon
- Where
- 72 sites in United States
- Volunteers
- 74 people
- Sponsor
- Takeda
Cognitive Impairments, Alzheimer Disease
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
The aim of the study is to evaluate the beneficial effect of a mixture of vegetal oils with a composition related to short, medium and long unsaturated chain fatty acids on patients with a diagnose of cognitive impairment or mild…
- Trial name
- NCT02778581
- Testing
- Lipidic Blend 1, Lipidic Blend 2
- Where
- 2 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Team Foods Colombia S.A.
COVID-19
Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation
This study is a randomized, double-blind, placebo-controlled I/II clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation in adults 18…
- Trial name
- NCT04840992
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Alzheimer's Disease
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild…
- Trial name
- PrevenTRON (NCT07717411)
- Testing
- Trontinemab
- Where
- 34 sites in United States, Argentina and 5 more
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Alzheimer´s Disease
AD01 Follow up Extension Visit
Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.
- Trial name
- NCT01225809
- Where
- Austria
- Volunteers
- 17 people
- Sponsor
- Affiris AG
Alzheimer Disease
ADvance DBS-f in Patients With Mild Probable Alzheimer's Disease
The primary objective of this feasibility study is to evaluate the safety of DBS-f in patients with mild Alzheimer's disease by assessing all device and/or therapy related adverse events.
- Trial name
- ADvance (NCT01608061)
- Testing
- DBS-f on, DBS-f off
- Where
- 7 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Functional Neuromodulation Ltd
Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies
- Trial name
- NCT02319005
- Testing
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Where
- 61 sites in United States, Belgium and 7 more
- Volunteers
- 206 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
ExAblate Blood-Brain Barrier Opening for Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of the ExAblate® Model 4000 Type 2.0 system as a tool to open the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
- Trial name
- NCT03739905
- Testing
- Blood Brain Barrier (BBB) Disruption
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- InSightec
Alzheimer's Disease
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
- Trial name
- NCT05804383
- Testing
- BMS-984923
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Allyx Therapeutics
Alzheimer Disease
Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease
The purpose of the study is to evaluate the safety and tolerability of multiple doses of NPT088 in patients with mild to moderate probable Alzheimer's Disease.
- Trial name
- NCT03008161
- Testing
- NPT088
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- Proclara Biosciences, Inc.
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Alzheimer's Disease
Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease
The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.
- Trial name
- NCT00704782
- Testing
- dimebon
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medivation, Inc.
Alzheimer Disease
Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease
The goal of this clinical study is to evaluate satisfaction with the use of orodispersible Memantine (OD) versus conventional Memantine tablets (MTb) using the validate SATMED-Q in patients with moderate to severe Alzheimer's…
- Trial name
- NCT07417670
- Testing
- Memantine, Memantine Oral Tablet
- Where
- 4 sites in Mexico
- Volunteers
- 105 people
- Sponsor
- Carnot Laboratories
Alzheimer Disease
Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
This is a phase 2b randomized, double-blind, Placebo-controlled study with 2 treatment arms, to compare the efficacy and safety of AstroStem vs. Placebo treatment in patients with mild Alzheimer's Disease(AD).
- Trial name
- NCT04482413
- Testing
- AstroStem
- Volunteers
- 100 people
- Sponsor
- Nature Cell Co. Ltd.
Alzheimer Disease
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to assess how well Donanemab is tolerated and what side effects may occur in Indian participants with early symptoms of Alzheimer's Disease (AD).
- Trial name
- NCT07838155
- Testing
- Donanemab
- Where
- 12 sites in India
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease, Dementia
Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance.
- Conditions
- Alzheimer's Disease, Dementia, Memory Loss, Cognitive Impairment
- Trial name
- NCT01354691
- Testing
- ladostigil hemitartrate
- Where
- 19 sites in Austria, Croatia and 3 more
- Volunteers
- 200 people
- Sponsor
- Avraham Pharmaceuticals Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.